MannKind (MNKD) shares are down 39%, or $2.14, to $3.40 in morning trading.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MNKD:
- Is MNKD a Buy, Before Earnings?
- MannKind: Pediatric Expansion, Improved Dosing, and Pipeline Diversification Drive Buy Rating on Afrezza Growth Potential
- MannKind says first patient enrolled in INHALE-1ST study of Afrezza
- Morning Movers: USA Rare Earth surges after government funding pact
- MannKind receives FDA approval for Afrezza dosage label